• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Influenza A And B Infections - Pipeline Review, H2 2012 Product Image

Influenza A And B Infections - Pipeline Review, H2 2012

  • Published: October 2012
  • 42 pages
  • Global Markets Direct

Influenza A And B Infections – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Influenza A And B Infections - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Influenza A And B Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Influenza A And B Infections. Influenza A And B Infections - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Influenza A And B Infections.
- A review of the Influenza A And B Infections READ MORE >

2
List of Tables 4
List of Figures 4
Introduction 5
REPORT COVERAGE 5
Influenza A And B Infections Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Influenza A And B Infections 7
Influenza A And B Infections Therapeutics under Development by Companies 9
Influenza A And B Infections Therapeutics under Investigation by Universities/Institutes 10
Late Stage Products 11
Comparative Analysis 11
Early Clinical Stage Products 12
Comparative Analysis 12
Discovery and Pre-Clinical Stage Products 13
Comparative Analysis 13
Influenza A And B Infections Therapeutics – Products under Development by Companies 14
Influenza A And B Infections Therapeutics – Products under Investigation by Universities/Institutes 15
Companies Involved in Influenza A And B Infections Therapeutics Development 16
Aphios Corporation 16
Toyama Chemical Co. Ltd 17
Crucell N.V. 18
Colby Pharmaceutical Company 19
Influenza A And B Infections – Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Combination Products 21
Assessment by Route of Administration 22
Assessment by Molecule Type 24
Drug Profiles 26
favipiravir - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
APP-0206s - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
CXF-Y2 - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
JVRS-100 + Universal Influenza Vaccine - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
peramivir - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
CR-9114 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Influenza A And B Infections Therapeutics – Drug Profile Updates 33
Influenza A And B Infections – Product Development Milestones 34
Featured News & Press Releases 34
May 01, 2012: Sanofi Pasteur Presents Phase III Quadrivalent Influenza Vaccine Data At Annual Meeting Of Pediatric Academic Societies 34
Jun 27, 2011: Biota Announces Preliminary Phase III Prophylaxis Trial Results For CS-8958 35
Jul 23, 2010: Flumist Begins Shipping For 2010-2011 Influenza Season 36
Dec 23, 2009: FDA Approves A High Dose Seasonal Influenza Vaccine Specifically Intended for People Ages 65 and Older 37
Dec 23, 2009: FDA Licenses New Influenza Vaccine Designed Specifically for People 65 Years of Age and Older 37
Sep 28, 2009: Merck & Co., Inc. Obtains Exclusive U.S. Marketing Rights for AFLURIA, Seasonal Influenza Vaccine from CSL Biotherapies 37
Jul 28, 2009: FluMist Begins Shipping for 2009-2010 Influenza Season 38
May 08, 2009: Juvaris BioTherapeutics’ Universal Influenza Vaccine Protects from Lethal H1N1 and H3N2 Challenges in Pre-Clinical Studies 38
May 05, 2009: FluMist Shows Acceptable Safety Profile in Immunocompromised Children, According to New Findings Presented at Pediatric Academic Societies Annual Meeting 39
Feb 26, 2009: INTANZA/IDflu first intradermal influenza vaccine, approved in the European Union 40
Appendix 41
Methodology 41
Coverage 41
Secondary Research 41
Primary Research 41
Expert Panel Validation 41
Contact Us 42
Disclaimer 42

List of Tables
Number of Products Under Development for Influenza A And B Infections, H2 2012 7
Products under Development for Influenza A And B Infections – Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 9
Number of Products under Investigation by Universities/Institutes, H2 2012 10
Comparative Analysis by Late Stage Development, H2 2012 11
Comparative Analysis by Early Clinical Stage Development, H2 2012 12
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 13
Products under Development by Companies, H2 2012 14
Products under Investigation by Universities/Institutes, H2 2012 15
Aphios Corporation, H2 2012 16
Toyama Chemical Co. Ltd, H2 2012 17
Crucell N.V., H2 2012 18
Colby Pharmaceutical Company, H2 2012 19
Assessment by Monotherapy Products, H2 2012 20
Assessment by Combination Products, H2 2012 21
Assessment by Stage and Route of Administration, H2 2012 23
Assessment by Stage and Molecule Type, H2 2012 25
Influenza A And B Infections Therapeutics – Drug Profile Updates 33

List of Figures
Number of Products under Development for Influenza A And B Infections, H2 2012 7
Products under Development for Influenza A And B Infections – Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Products under Investigation by Universities/Institutes, H2 2012 10
Late Stage Products, H2 2012 11
Early Clinical Stage Products, H2 2012 12
Discovery and Pre-Clinical Stage Products, H2 2012 13
Assessment by Monotherapy Products, H2 2012 20
Assessment by Combination Products, H2 2012 21
Assessment by Route of Administration, H2 2012 22
Assessment by Stage and Route of Administration, H2 2012 23
Assessment by Molecule Type, H2 2012 24
Assessment by Stage and Molecule Type, H2 2012 25

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos